Orexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $14.07 million.

According to IMS Health, 185,944 prescriptions of Contrave (naltrexone HCl and bupropion HCl extended-release tablets) were filled in the fourth quarter of 2015.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.